Literature DB >> 31888886

Wnt-Induced Stabilization of KDM4C Is Required for Wnt/β-Catenin Target Gene Expression and Glioblastoma Tumorigenesis.

Yaohui Chen1, Runping Fang1,2, Chen Yue1, Guoqiang Chang2, Peng Li2, Qing Guo1, Jing Wang3, Aidong Zhou1, Sicong Zhang1, Gregory N Fuller4,5, Xiaobing Shi5,6,7, Suyun Huang8,2,5.   

Abstract

Wnt/β-catenin signaling activates the transcription of target genes to regulate stem cells and cancer development. However, the contribution of epigenetic regulation to this process is unknown. Here, we report that Wnt activation stabilizes the epigenetic regulator KDM4C that promotes tumorigenesis and survival of human glioblastoma cells by epigenetically activating the transcription of Wnt target genes. KDM4C protein expression was upregulated in human glioblastomas, and its expression directly correlated with Wnt activity and Wnt target gene expression. KDM4C was essential for Wnt-induced gene expression and tumorigenesis of glioblastoma cells. In the absence of Wnt3a, protein kinase R phosphorylated KDM4C at Ser918, inducing KDM4C ubiquitination and degradation. Wnt3a stabilized KDM4C through inhibition of GSK3-dependent protein kinase R activity. Stabilized KDM4C accumulated in the nucleus and bound to and demethylated TCF4-associated histone H3K9 by interacting with β-catenin, promoting HP1γ removal and transcriptional activation. These findings reveal that Wnt-KDM4C-β-catenin signaling represents a novel mechanism for the transcription of Wnt target genes and regulation of tumorigenesis, with important clinical implications. SIGNIFICANCE: These findings identify the Wnt-KDM4C-β-catenin signaling axis as a critical mechanism for glioma tumorigenesis that may serve as a new therapeutic target in glioblastoma. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31888886      PMCID: PMC7360480          DOI: 10.1158/0008-5472.CAN-19-1229

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines.

Authors:  Bradley W Doble; Satish Patel; Geoffrey A Wood; Lisa K Kockeritz; James R Woodgett
Journal:  Dev Cell       Date:  2007-06       Impact factor: 12.270

2.  The histone demethylase JMJD2C is stage-specifically expressed in preimplantation mouse embryos and is required for embryonic development.

Authors:  Jianle Wang; Miao Zhang; Yu Zhang; Zhaohui Kou; Zhiming Han; Da-Yuan Chen; Qing-Yuan Sun; Shaorong Gao
Journal:  Biol Reprod       Date:  2009-08-19       Impact factor: 4.285

Review 3.  Mechanisms of functional promiscuity by HP1 proteins.

Authors:  Daniele Canzio; Adam Larson; Geeta J Narlikar
Journal:  Trends Cell Biol       Date:  2014-03-04       Impact factor: 20.808

4.  Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL.

Authors:  Vipul C Chitalia; Rebecca L Foy; Markus M Bachschmid; Liling Zeng; Maria V Panchenko; Mina I Zhou; Ajit Bharti; David C Seldin; Stewart H Lecker; Isabel Dominguez; Herbert T Cohen
Journal:  Nat Cell Biol       Date:  2008-09-21       Impact factor: 28.824

Review 5.  The definition of primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

6.  Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes.

Authors:  Louisa M Villeneuve; Marpadga A Reddy; Linda L Lanting; Mei Wang; Li Meng; Rama Natarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-25       Impact factor: 11.205

7.  Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.

Authors:  Shinzo Yamamoto; Keisuke Tateishi; Yotaro Kudo; Keisuke Yamamoto; Takayuki Isagawa; Genta Nagae; Takuma Nakatsuka; Yoshinari Asaoka; Hideaki Ijichi; Yoshihiro Hirata; Motoyuki Otsuka; Tsuneo Ikenoue; Hiroyuki Aburatani; Masao Omata; Kazuhiko Koike
Journal:  Carcinogenesis       Date:  2013-05-22       Impact factor: 4.944

8.  Tumour suppressor TRIM33 targets nuclear β-catenin degradation.

Authors:  Jianfei Xue; Yaohui Chen; Yamei Wu; Zhongyong Wang; Aidong Zhou; Sicong Zhang; Kangyu Lin; Kenneth Aldape; Sadhan Majumder; Zhimin Lu; Suyun Huang
Journal:  Nat Commun       Date:  2015-02-02       Impact factor: 14.919

9.  Distinct and combinatorial functions of Jmjd2b/Kdm4b and Jmjd2c/Kdm4c in mouse embryonic stem cell identity.

Authors:  Partha Pratim Das; Zhen Shao; Semir Beyaz; Eftychia Apostolou; Luca Pinello; Alejandro De Los Angeles; Kassandra O'Brien; Jennifer Marino Atsma; Yuko Fujiwara; Minh Nguyen; Damir Ljuboja; Guoji Guo; Andrew Woo; Guo-Cheng Yuan; Tamer Onder; George Daley; Konrad Hochedlinger; Jonghwan Kim; Stuart H Orkin
Journal:  Mol Cell       Date:  2013-12-19       Impact factor: 17.970

10.  KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis.

Authors:  Ilana Kupershmit; Hanan Khoury-Haddad; Samah W Awwad; Noga Guttmann-Raviv; Nabieh Ayoub
Journal:  Nucleic Acids Res       Date:  2014-04-11       Impact factor: 16.971

View more
  19 in total

1.  Modeling breast cancer survival and metastasis rates from moderate-sized clinical data.

Authors:  Esha Maiti
Journal:  Clin Exp Metastasis       Date:  2021-01-03       Impact factor: 5.150

Review 2.  Epigenetic regulation of cancer stem cell and tumorigenesis.

Authors:  Kezhou Zhu; Victoria Xie; Suyun Huang
Journal:  Adv Cancer Res       Date:  2020-07-16       Impact factor: 6.242

Review 3.  Recent Advances with KDM4 Inhibitors and Potential Applications.

Authors:  Qiong Wu; Brandon Young; Yan Wang; Andrew M Davidoff; Zoran Rankovic; Jun Yang
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039

Review 4.  Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior.

Authors:  Vigneshwari Easwar Kumar; Roshni Nambiar; Cristabelle De Souza; Audrey Nguyen; Jeremy Chien; Kit S Lam
Journal:  Cells       Date:  2022-04-21       Impact factor: 7.666

5.  Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NF-κB/STAT3 Signaling.

Authors:  Markus W Schweiger; Mao Li; Alberta Giovanazzi; Renata L Fleming; Elie I Tabet; Ichiro Nakano; Thomas Würdinger; Ennio Antonio Chiocca; Tian Tian; Bakhos A Tannous
Journal:  Adv Biosyst       Date:  2020-06-09

6.  SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.

Authors:  Julia Y Tsang; Sui-Ting Lai; Yun-Bi Ni; Yan Shao; Ivan K Poon; Johnny S Kwan; Chit Chow; Ka-Ho Shea; Gary M Tse
Journal:  Breast Cancer Res Treat       Date:  2021-04-12       Impact factor: 4.872

7.  Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling.

Authors:  Hui Shi; Luping Zhao; Xinlin Guo; Runping Fang; Hui Zhang; Guanjun Dong; Jia Fu; Fenglian Yan; Junfeng Zhang; Zhaochen Ning; Qun Ma; Zhihua Li; Chunxia Li; Jun Dai; Chuanping Si; Huabao Xiong
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

8.  Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.

Authors:  Wei Wu; Jessica L Klockow; Michael Zhang; Famyrah Lafortune; Edwin Chang; Linchun Jin; Yang Wu; Heike E Daldrup-Link
Journal:  Pharmacol Res       Date:  2021-07-21       Impact factor: 10.334

9.  IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases.

Authors:  Rosalie G Hoyle; Huiqun Wang; Yana Cen; Yan Zhang; Jiong Li
Journal:  Mol Cancer Ther       Date:  2020-11-17       Impact factor: 6.009

Review 10.  Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance.

Authors:  Zulfikar Azam; Shing-Shun Tony To; Bakhos A Tannous
Journal:  Adv Sci (Weinh)       Date:  2020-09-28       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.